Video: Healthcast - New FDA-approved infusion drugs for early stage Alzheimer’s
Lecanemab (Leqembi®) and donanemab (Kisunla®) are two new FDA-approved drugs, administered intravenously, that can slow cognitive decline in people diagnosed with early-stage Alzheimer’s. While not a cure, they can slow the progression of the disease and are available at the Stony Brook Center of Excellence for Alzheimer’s Disease, one of only 10 such centers in New York State and the only one on Long Island. Learn how these infusion drugs work, and how to find out if you or a loved one qualify for treatment, while also learning about other services, resources and more that Stony Brook Medicine has to offer to help Long Island’s aging population.
Share:
More Stories
Click HERE to watch.
